We are live on ! Find out more
ARDS

Aridis Pharmaceuticals Inc. Common Stock
ARDS

Delisted

ARDS was delisted on the 18th of July, 2023.

Back to rankings

6 hedge funds and large institutions have $725K invested in Aridis Pharmaceuticals Inc. Common Stock in 2018 Q3 according to their latest regulatory filings, with 6 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed
Holders
6
Holders Change
+6
Holders Change %
–
% of All Funds
0.14%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
6
Increased
–
Reduced
–
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Goldman Sachs
Goldman Sachs
New York
+$366K
2
Millennium Management
Millennium Management
New York
+$305K
3
UBS Group
UBS Group
Switzerland
+$23.4K
4
SPIA
Steward Partners Investment Advisory
New York
+$12.9K
5
TRCT
Tower Research Capital (TRC)
New York
+$8.08K

Top Sellers

No sellers this quarter
Name Holding Trade Value Shares
Change 		Change in
Stake
Goldman Sachs
1
Goldman Sachs
New York
$370K +$366K +28,348 New
Millennium Management
2
Millennium Management
New York
$306K +$305K +23,585 New
UBS Group
3
UBS Group
Switzerland
$24K +$23.4K +1,809 New
SPIA
4
Steward Partners Investment Advisory
New York
$13K +$12.9K +1,000 New
TRCT
5
Tower Research Capital (TRC)
New York
$8K +$8.08K +625 New
Wells Fargo
6
Wells Fargo
California
$4K +$3.88K +300 New

ARDS Hedge Fund Activity: Q3 2018 in Review

6 of the 4,375 institutional investors tracked by Wall St. Rank reported a position in Aridis Pharmaceuticals Inc. Common Stock (ARDS) for Q3 2018, worth a combined $725K.

Buyers outnumbered sellers: 6 funds opened new ARDS positions and 0 closed out — a net gain of 6 holders — while 0 added to existing stakes and 0 trimmed.

The largest buyer was Goldman Sachs, opening a new position worth an estimated $366K.

  • 6 institutional investors held Aridis Pharmaceuticals Inc. Common Stock (ARDS) as of Q3 2018, up from 0 in Q2 2018.
  • Funds reported $725K of Aridis Pharmaceuticals Inc. Common Stock stock for Q3 2018.
  • 6 funds opened new Aridis Pharmaceuticals Inc. Common Stock positions in Q3 2018 and 0 closed out, a net change of +6 holders.
  • The largest Aridis Pharmaceuticals Inc. Common Stock buyer in Q3 2018 was Goldman Sachs, an estimated $366K added.

Based on aggregated 13F filings for Q3 2018.